FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

OIVIB APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	rden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Katkin Keith						2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ]									ck all app	licable)	,			
(Last) (First) (Middle) 300 PROFESSIONAL DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 05/23/2025									Office below	er (give title /)		Other (below)	specify		
(Street) GAITHERSBURG MD 20879 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person  Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day						Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Ac Disposed Of (D							ies cially Following	Form (D) o	n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
				Code	v	Amount	(A) (D)	or F	Price	Report Transa (Instr. 3				(Instr. 4)						
Common Stock 05/23/2						2025 05/23/2		025	S		7,844(1)	Г	)	\$6.3 <sup>(2</sup>	86,431			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o	r osed ) r. 3, 4	6. Date Expirati (Month/	ion Da	Year) Securities Underlying Derivative Security (Ins 3 and 4)  Amou		str.	. Price of Perivative Pecurity Pecurity Pecurity	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Num of Shar							

## **Explanation of Responses:**

- 1. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 8, 2024, for the purpose of satisfying tax obligations relating to the vesting of RSUs on May 22, 2025.
- 2. For reporting purposes, sales prices within a \$1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: \$6.22 \$6.35. The Company maintains a record of the transactions and copies will be provided upon request.

## Remarks:

/s/ Richard S. Lindahl, Attorney-in-fact

05/28/2025

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.